Prostate Cancer Drugs: Billions of Abiraterone May Be Purchased
1.Till December 6, 2019, the top three Chinese generic drug abiraterone tablets are currently approved: Hengrui
Pharmaceutical's Ai Sente in July 2019; Zhengda Tianqing Pharmaceutical Group's Qing Ke Shu; and Xin Yang from Qingfeng Pharmaceutical (Jiangxi Shanxiang Pharmaceutical) in September 2019.
According to relevant data, the prices of the generic drugs learned are in the order of 12,800 yuan / 120 tablets / bottle (250mg), 12,200 yuan / 120 tablets / bottle (250mg), and 11,800 yuan / 120 tablets / bottle (250mg). (Among them, Hengrui Pharmaceutical's investment in research and development of this product is about 39.05 million yuan)
In addition, Qilu Pharmaceutical and India's Dr. Reddy`s Abiraterone tablets are also under review. Qilu Pharmaceutical has been approved for listing in the United States (Abbreviated New Drug Application: 212462, QILU PHARM CO LTD, becoming one of the nine generic drug companies in the US market).
Two:Original research abiraterone acetate (Zeke) In 2015, the abiraterone acetate (trade name: Zeke) developed by Janssen-Cilag was approved in China, and Xi'an Yangsen was responsible for it in China. On September 25, 2019, Zeke's performance in the Chinese market exceeded 1 billion yuan.
Abiraterone acetate is converted into abiraterone in the body, which is an androgen biosynthesis inhibitor that inhibits 17α-hydroxylase / C17,20-lyase (CYP17).
Currently approved indications in China: combined with prednisone to treat metastatic castration-resistant prostate cancer (mCRPC) (metastatic castration-resistant prostate cancer); newly diagnosed high-risk metastatic endocrine therapy-sensitive prostate (mHSPC) ( metastatic hormone-sensitive prostate cancer), including no endocrine therapy or endocrine therapy for up to 3 months.
It is reported that Johnson & Johnson Abiraterone (foreign trade name: Zytiga) achieved sales of 3.498 billion yuan (peak sales) in FY2018, an increase of 39.6% year-on-year. Johnson & Johnson's 2019Q1 performance report data was 679 million US dollars, down 19.6% year-on-year. The semi-annual report for 2019 shows that Abiraterone sales were 1.377 billion US dollars, down 21.5% year-on-year. In the first three quarters of 2019, Abiraterone's performance was US $ 2.118 billion, a year-on-year decrease of 21.9%.
According to relevant data: In 2015, the original research Abiraterone (Zeke) was 36925 yuan 120 tablets / bottle (250mg) at the beginning. In 2017, after the national health insurance negotiations, prices fell by about 53%. At present, the original retail price of Abiraterone (Zeke) is about 16268 yuan / 120 tablets / bottle (250mg) in China.
Three:Prostate cancer Prostate cancer is the second most common tumor type in men worldwide, with approximately 1.3 million newly diagnosed patients worldwide in 2018. In China, prostate cancer is the most common genitourinary cancer in men, with an incidence rate of approximately 9.8 per 100,000. The latest data released by the National Cancer Center in 2019 shows that lung cancer is the first male disease, and prostate cancer is the sixth most common disease. The top 10 malignant tumors accounted for about 82.20% of all male malignancies.
Four:Suddenly At the end of November 2019, the "Notice on Reporting the Expansion of the Procurement Data Relevant to the Expansion of the National Organizations' Centralized Procurement and Use of Drug Varieties" was spread among pharmaceutical companies. The first to come into view is the oral release of abiraterone.
On December 6, 2019, in Shanghai, a new round of national volume procurement work conference was held. It is reported that the policy has undergone new easing.
With the approval of the third Chinese abiraterone, the market for generic drugs in exchange for price will become more intense. Perhaps, in 2020, abiraterone will be included in centralized drug procurement. In the future, high-quality generic drugs will benefit domestic patients together with original research drugs!
